Literature DB >> 15246916

Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy.

Márta Högye1, Yvette Mándi, Miklós Csanády, Róbert Sepp, Krisztina Buzás.   

Abstract

It is known from the literature that the circulating levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) are elevated in heart failure and idiopathic dilated cardiomyopathy (IDC). Few convincing data are available on the production of cytokines in hypertrophic cardiomyopathy (HC). The levels of circulating IL-6, the soluble form of the IL-6 receptor (sIL-6R), and TNF-alpha in 19 patients with HC, 31 patients with IDC, and 20 healthy subjects (control group) were examined and compared with their clinical parameters. The levels of TNF-alpha and circulating IL-6 proved to be elevated in the sera of patients with IDC. In contrast, the level of TNF-alpha was not elevated in HC, although the levels of IL-6 and sIL-6R were significantly higher than those in the sera of patients with IDC. Although elevated levels of IL-6 may correlate with the extent of left ventricular dysfunction in IDC, the markedly elevated IL-6 levels did not correlate with left ventricular function in HC. The markedly elevated TNF-alpha levels in IDC were associated with the elevated IL-6 levels, probably because of an inflammatory process and/or heart failure. In contrast, in HC, in which the New York Heart Association functional class was actually good, the even higher IL-6 and sIL-6R levels were not associated with a TNF-alpha elevation. In HC, the IL-6 and sIL-6R elevations were due to another mechanism, probably by way of the cardiotrophin-associated gp130 receptor. The sources of IL-6 production in HC are not clear yet.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246916     DOI: 10.1016/j.amjcard.2004.03.078

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  20 in total

1.  Usefulness of Serum Omentin-1 Levels for the Prediction of Adverse Cardiac Events in Patients with Hypertrophic Cardiomyopathy.

Authors:  Suleyman Sezai Yıldız; Irfan Sahin; Gokhan Cetinkal; Gokhan Aksan; Suat Hayri Kucuk; Kudret Keskin; Sukru Cetin; Serhat Sigirci; İlhan İlker Avcı; Hakan Kilci; Kadriye Kiliçkesmez
Journal:  Med Princ Pract       Date:  2018-03-22       Impact factor: 1.927

2.  Assessment of cardiotoxicity with cardiac biomarkers in cancer patients.

Authors:  D Cardinale; C M Cipolla
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

Review 3.  STAT3 and cardiac remodeling.

Authors:  Arash Haghikia; Britta Stapel; Melanie Hoch; Denise Hilfiker-Kleiner
Journal:  Heart Fail Rev       Date:  2011-01       Impact factor: 4.214

4.  Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy.

Authors:  Lu Fang; Andris H Ellims; Anna L Beale; Andrew J Taylor; Andrew Murphy; Anthony M Dart
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

5.  Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure.

Authors:  Ercan Varol; Mehmet Ozaydin; Ahmet Altinbas; Suleyman M Aslan; Abdullah Dogan; Ozkan Dede
Journal:  Heart Vessels       Date:  2007-01-26       Impact factor: 2.037

6.  Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain.

Authors:  M Valenti; D Viganò; M G Casico; T Rubino; L Steardo; D Parolaro; V Di Marzo
Journal:  Cell Mol Life Sci       Date:  2004-04       Impact factor: 9.261

Review 7.  Role of cytokines and inflammation in heart function during health and disease.

Authors:  Monika Bartekova; Jana Radosinska; Marek Jelemensky; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

8.  Rapid, Fatal Acute Right Ventricular Failure After Locoregional Cytokine Therapy for Uveal Melanoma Liver Metastases.

Authors:  Rajiv A Kabadi; Mital Shah; Gregary D Marhefka; Gautam George; Bharat Awsare; Mizue Terai; Takami Sato
Journal:  Tex Heart Inst J       Date:  2020-06-01

9.  Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy.

Authors:  Johanna Kuusisto; Vesa Kärjä; Petri Sipola; Ivana Kholová; Keijo Peuhkurinen; Pertti Jääskeläinen; Anita Naukkarinen; Seppo Ylä-Herttuala; Kari Punnonen; Markku Laakso
Journal:  Heart       Date:  2012-03-24       Impact factor: 5.994

10.  Platelet activation in cats with hypertrophic cardiomyopathy.

Authors:  F Tablin; T Schumacher; M Pombo; C T Marion; K Huang; J W Norris; K E Jandrey; M D Kittleson
Journal:  J Vet Intern Med       Date:  2014-02-24       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.